| Market Cap | 23.26M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -9.13M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -6.00% |
| Sales | 866.79k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -3.00% |
| Dividend | N/A | Price/Book | 7.83 | EPS next 5Y | - | 52W High Chg | -68.00% |
| Recommedations | - | Quick Ratio | 0.36 | Shares Outstanding | 29.91M | 52W Low Chg | 64.00% |
| Insider Own | 36.20% | ROA | -57.51% | Shares Float | 19.08M | Beta | - |
| Inst Own | 1.64% | ROE | -108.44% | Shares Shorted/Prior | 203.94K/462.45K | Price | 1.41 |
| Gross Margin | 58.19% | Profit Margin | - | Avg. Volume | 1,012,198 | Target Price | - |
| Oper. Margin | -1,304.61% | Earnings Date | - | Volume | 255,617 | Change | -2.76% |
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Cohen Jacob D. | Chief Executive Offi.. Chief Executive Officer | Apr 04 | Buy | 1 | 275,000 | 275,000 | 8,275,000 | 05/02/23 |